Novel combination therapy shows promise for advanced neuroendocrine tumors A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented this week at the European Society for Medical Oncology (ESMO) Congress 2025.
https://www.news-medical.net/n....ews/20251021/Novel-c

Largest trial of adjuvant pembrolizumab in Merkel cell carcinoma reports key benefit A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the risk of distant metastases for an aggressive form of skin cancer when given immediately after surgery, but did not significantly reduce the overall risk of recurrence, which was a co-primary endpoint of the trial.
https://www.news-medical.net/n....ews/20251021/Largest

Targeted therapy combination shows superior outcomes in advanced kidney cancer Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.
https://www.news-medical.net/n....ews/20251018/Targete

Oral combination regimen improves survival in ER-positive HER-2-negative breast cancer Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.
https://www.news-medical.net/n....ews/20251018/Oral-co

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.
https://www.news-medical.net/n....ews/20251018/Belzuti